MX341536B - Epitopo y anticuerpos beta amiloide de oligomero especifico. - Google Patents

Epitopo y anticuerpos beta amiloide de oligomero especifico.

Info

Publication number
MX341536B
MX341536B MX2012010175A MX2012010175A MX341536B MX 341536 B MX341536 B MX 341536B MX 2012010175 A MX2012010175 A MX 2012010175A MX 2012010175 A MX2012010175 A MX 2012010175A MX 341536 B MX341536 B MX 341536B
Authority
MX
Mexico
Prior art keywords
epitope
amino acid
antibody
snk
oligomer
Prior art date
Application number
MX2012010175A
Other languages
English (en)
Spanish (es)
Other versions
MX2012010175A (es
Inventor
R Cashman Neil
Original Assignee
The Univ Of British Columbia *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44541581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX341536(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Univ Of British Columbia * filed Critical The Univ Of British Columbia *
Publication of MX2012010175A publication Critical patent/MX2012010175A/es
Publication of MX341536B publication Critical patent/MX341536B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2012010175A 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico. MX341536B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31016710P 2010-03-03 2010-03-03
PCT/CA2011/000238 WO2011106885A1 (en) 2010-03-03 2011-03-03 Oligomer-specific amyloid beta epitope and antibodies

Publications (2)

Publication Number Publication Date
MX2012010175A MX2012010175A (es) 2012-11-23
MX341536B true MX341536B (es) 2016-08-24

Family

ID=44541581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010175A MX341536B (es) 2010-03-03 2011-03-03 Epitopo y anticuerpos beta amiloide de oligomero especifico.

Country Status (17)

Country Link
US (3) US9216217B2 (https=)
EP (2) EP3056510B1 (https=)
JP (2) JP6190113B2 (https=)
KR (1) KR101831459B1 (https=)
CN (1) CN102858796B (https=)
AU (1) AU2011223456A1 (https=)
BR (1) BR112012022229A2 (https=)
CA (1) CA2791538C (https=)
CL (1) CL2012002438A1 (https=)
CO (1) CO6640211A2 (https=)
IL (1) IL221695B (https=)
MX (1) MX341536B (https=)
NZ (1) NZ602548A (https=)
RU (1) RU2644335C2 (https=)
SG (1) SG183854A1 (https=)
WO (1) WO2011106885A1 (https=)
ZA (1) ZA201206916B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
TWI571207B (zh) 2011-06-26 2017-02-21 安麗托克斯公司 用於條件化動物飼料之寒冷天氣調配物
CN104093454A (zh) * 2011-11-10 2014-10-08 坎格尼美国股份有限公司 治疗阿耳茨海默氏病的组合物和方法
JP6434903B2 (ja) * 2012-04-05 2018-12-05 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 多価アミロイドβに結合するＤ−ペプチド含有ポリマー及びその使用
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
CA3004494A1 (en) * 2015-11-09 2017-05-18 The University Of British Columiba Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
CA3004496A1 (en) * 2015-11-09 2017-05-18 Neil R. Cashman Epitopes in amyloid beta and conformationally-selective antibodies thereto
US10772969B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10759837B2 (en) 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
JP6952351B2 (ja) 2015-11-09 2021-10-20 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 集団座標バイアシングによりミスフォールディングタンパク質エピトープを予測するためのシステムおよび方法
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2020033756A1 (en) * 2018-08-09 2020-02-13 F. Hoffmann-La Roche Ag Determination of parkinson's disease
JP7719713B2 (ja) * 2018-10-07 2025-08-06 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア α－シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021055670A1 (en) 2019-09-20 2021-03-25 Avx Corporation Somatic cell-based electrical biosensor
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP0890105B1 (en) * 1996-03-29 2006-11-22 The Trustees Of Boston University Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7252952B2 (en) 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US6686443B1 (en) 2000-05-26 2004-02-03 The Regents Of The University Of California Chemical reagents for formation of disulfide bonds in peptides
DE04759123T1 (de) 2003-04-07 2005-08-18 Novetide Ltd. Verfahren zur herstellung cyclischer peptide
EP1484336A1 (en) 2003-06-02 2004-12-08 Pevion Biotech Ltd. Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines
WO2006047254A1 (en) * 2004-10-22 2006-05-04 Regents Of The University Of Minnesota Assemblies of oligomeric amyloid beta protein and uses thereof
IL169622A0 (en) 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
EP1907423A4 (en) * 2005-07-13 2010-01-13 Coimmune Inc CATALYTIC IMMUNOGLOBULINE
US9365622B2 (en) 2006-03-01 2016-06-14 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
US9045555B2 (en) * 2008-07-01 2015-06-02 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
JP2011529084A (ja) * 2008-07-25 2011-12-01 アボット・ラボラトリーズ アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用
WO2010010469A2 (en) 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
US8410243B2 (en) 2008-12-17 2013-04-02 The Governors Of The University Of Alberta Aromatic ether-containing fluorene monomers, processes for their preparation and polymerization thereof
US20110306605A1 (en) 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
KR20130043088A (ko) 2010-02-09 2013-04-29 브리스톨-마이어스 스큅 컴퍼니 면역검정 표준물 및 검정내 보정 표준물을 사용한 임상 바이오마커의 측정
RU2644335C2 (ru) 2010-03-03 2018-02-08 Зе Юниверсити Оф Бритиш Коламбия Эпитоп, специфичный к олигомеру амилоида бета, и антитела
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
CN104093454A (zh) 2011-11-10 2014-10-08 坎格尼美国股份有限公司 治疗阿耳茨海默氏病的组合物和方法

Also Published As

Publication number Publication date
WO2011106885A1 (en) 2011-09-09
MX2012010175A (es) 2012-11-23
EP3056510B1 (en) 2018-10-03
RU2644335C2 (ru) 2018-02-08
JP6190113B2 (ja) 2017-08-30
CO6640211A2 (es) 2013-03-22
EP2542571A4 (en) 2013-07-31
EP2542571A1 (en) 2013-01-09
BR112012022229A2 (pt) 2016-07-05
JP2013524774A (ja) 2013-06-20
US20140314773A1 (en) 2014-10-23
US20130084283A1 (en) 2013-04-04
CA2791538C (en) 2019-04-16
CN102858796B (zh) 2016-05-11
AU2011223456A1 (en) 2012-10-18
US9849165B2 (en) 2017-12-26
CL2012002438A1 (es) 2013-09-13
US9216217B2 (en) 2015-12-22
CA2791538A1 (en) 2011-09-09
NZ602548A (en) 2014-12-24
US20160228522A1 (en) 2016-08-11
EP3056510A1 (en) 2016-08-17
IL221695B (en) 2019-01-31
JP2016193914A (ja) 2016-11-17
ZA201206916B (en) 2014-03-26
KR101831459B1 (ko) 2018-04-04
CN102858796A (zh) 2013-01-02
KR20130045850A (ko) 2013-05-06
EP2542571B1 (en) 2016-05-25
RU2012139043A (ru) 2014-04-10
SG183854A1 (en) 2012-10-30
JP6494565B2 (ja) 2019-04-03

Similar Documents

Publication Publication Date Title
MX341536B (es) Epitopo y anticuerpos beta amiloide de oligomero especifico.
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
AU2018256498A1 (en) Antibodies to amyloid beta
TW200732348A (en) Monoclonal antibody
MX341369B (es) Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
EA201000809A1 (ru) АНТИТЕЛА, СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ ПРОТОФИБРИЛЛЯРНОЙ ФОРМЫ БЕЛКА β-АМИЛОИДА
TR201800669T4 (tr) Alzheimer hastaliğinda tau-aracili patoloji̇ni̇n tanilanmasi ve protei̇n bazli tedavi̇si̇
MX2009003468A (es) Anticuerpo humanizado contra beta amiloide.
MX2011012039A (es) Anticuerpos bloqueadores anti-dkk-1 y sus usos.
EP2403871A4 (en) FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES
EA201300130A1 (ru) Способ лечения болезни альцгеймера
PH12012501743A1 (en) Antigen binding proteins specific for serum amyloid p component
WO2012021475A3 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
MX2011012677A (es) Conjugados de albumina-peptido amiloide y usos de los mismos.
WO2020069050A3 (en) Methods of treating neurodegenerative diseases
MX343873B (es) Ensayo de diagnostico de anticuerpo.
MX2012004448A (es) Clones infecciosos de torque teno virus.
WO2013054110A3 (en) Compositions for binding to amyloid proteins
TH95385B (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์
RU2019123453A (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа
TH95385A (th) แอนติบอดีที่ได้รับการฮิวมาไนซ์

Legal Events

Date Code Title Description
FG Grant or registration